Core Insights - Galecto, Inc. reported its operating and financial results for Q3 2025, highlighting progress in its clinical development pipeline, particularly for GB3226, a novel treatment for acute myeloid leukemia (AML) [1][2]. Financial Performance - As of September 30, 2025, cash and cash equivalents were approximately $7.6 million, which is expected to fund preclinical development into 2026, but additional capital will be needed for future clinical development [3]. - Research and development expenses increased to $1.4 million in Q3 2025 from $1.1 million in Q3 2024, primarily due to higher costs in chemistry, manufacturing, and control, as well as preclinical studies [4]. - General and administrative expenses decreased to $1.7 million in Q3 2025 from $2.7 million in Q3 2024, mainly due to reduced personnel and legal costs [5]. - The net loss attributable to common stockholders for Q3 2025 was $3.1 million, or $(2.36) per share, compared to a net loss of $3.9 million, or $(3.39) per share, in the prior year [6]. Development Pipeline - The company received positive regulatory feedback from the FDA regarding its pre-IND submission for GB3226, which is aimed at treating a broad range of AML patients, including those with high-risk genetic mutations [2]. - Preclinical data supports the potential of GB3226 to treat AML, either as a monotherapy or in combination with existing treatments, with plans for a Phase 1 trial to assess safety and efficacy [2]. Company Overview - Galecto is focused on developing novel treatments for oncology and liver diseases, with a pipeline that includes GB1211 for liver cirrhosis and GB3226 for AML [7].